228 related articles for article (PubMed ID: 32794105)
1. The deep learning model combining CT image and clinicopathological information for predicting ALK fusion status and response to ALK-TKI therapy in non-small cell lung cancer patients.
Song Z; Liu T; Shi L; Yu Z; Shen Q; Xu M; Huang Z; Cai Z; Wang W; Xu C; Sun J; Chen M
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):361-371. PubMed ID: 32794105
[TBL] [Abstract][Full Text] [Related]
2. Association of anaplastic lymphoma kinase variants and alterations with ensartinib response duration in non-small cell lung cancer.
Hou D; Zheng X; Song W; Liu X; Wang S; Zhou L; Tao X; Lv L; Sun Q; Jin Y; Zhang Z; Ding L; Wu N; Zhao S
Thorac Cancer; 2021 Sep; 12(17):2388-2399. PubMed ID: 34288491
[TBL] [Abstract][Full Text] [Related]
3. Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study.
Tan X; Li Y; Wang S; Xia H; Meng R; Xu J; Duan Y; Li Y; Yang G; Ma Y; Jin Y
Respir Res; 2022 May; 23(1):132. PubMed ID: 35624472
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological and computed tomography features of patients with early-stage non-small-cell lung cancer harboring ALK rearrangement.
Hou X; Chen H; Liu Y; Gong S; Zhudai M; Shen L
Cancer Imaging; 2023 Feb; 23(1):20. PubMed ID: 36823653
[TBL] [Abstract][Full Text] [Related]
5. Correlation between combining
Ruan M; Liu L; Wang L; Lei B; Sun X; Chang C; Shen Y; Xie W
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1183-1197. PubMed ID: 31897590
[TBL] [Abstract][Full Text] [Related]
6. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
7. ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization.
Yamamoto S; Korn RL; Oklu R; Migdal C; Gotway MB; Weiss GJ; Iafrate AJ; Kim DW; Kuo MD
Radiology; 2014 Aug; 272(2):568-76. PubMed ID: 24885982
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological Features in Elderly ALK-rearranged Non-small Cell Lung Cancer Patients.
Miyazaki K; Sato S; Kodama T; Numata T; Endo T; Yamamoto Y; Shimizu K; Yamada H; Hayashihara K; Okauchi S; Satoh H; Yamada Y; Tamura T; Saito K; Kikuchi N; Kurishima K; Ishikawa H; Watanabe H; Shiozawa T; Hizawa N; Funayama Y; Hayashi S; Nakamura H; Yamashita T
In Vivo; 2020; 34(4):2001-2007. PubMed ID: 32606173
[TBL] [Abstract][Full Text] [Related]
9. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
10. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
[TBL] [Abstract][Full Text] [Related]
11. Predicting anaplastic lymphoma kinase rearrangement status in patients with non-small cell lung cancer using a machine learning algorithm that combines clinical features and CT images.
Hao P; Deng BY; Huang CT; Xu J; Zhou F; Liu ZX; Zhou W; Xu YK
Front Oncol; 2022; 12():994285. PubMed ID: 36338735
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
13. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
14. Environment-Sensitive Fluorescent Probe Enables Assessment of Anaplastic Lymphoma Kinase Activity in Nonsmall Cell Lung Cancer.
Zhou X; Lei Q; Xiao Z; Song C; Deng H
Anal Chem; 2024 Feb; 96(8):3525-3534. PubMed ID: 38345335
[TBL] [Abstract][Full Text] [Related]
15. Pretherapy investigations using highly robust visualized biomarkers from CT imaging by multiple machine-learning techniques toward its prognosis prediction for ALK-inhibitor therapy in NSCLC: a feasibility study.
Sun J; Li F; Yang J; Lin C; Zhou X; Liu N; Zhang B; Song G; Wang W; Huang C; Song Z; Shi L
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7341-7353. PubMed ID: 36928998
[TBL] [Abstract][Full Text] [Related]
16. CT Characteristics of Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangement: A Systematic Review and Meta-Analysis.
Kim TH; Woo S; Yoon SH; Halpenny DF; Han S; Suh CH
AJR Am J Roentgenol; 2019 Nov; 213(5):1059-1072. PubMed ID: 31414902
[No Abstract] [Full Text] [Related]
17. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
18. Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice.
Jamme P; Descarpentries C; Gervais R; Dansin E; Wislez M; Grégoire V; Richard N; Baldacci S; Rabbe N; Kyheng M; Kherrouche Z; Escande F; Copin MC; Cortot AB
Clin Lung Cancer; 2019 Jul; 20(4):297-304.e1. PubMed ID: 31147208
[TBL] [Abstract][Full Text] [Related]
19. Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patients.
Haratake N; Seto T; Takamori S; Toyozawa R; Nosaki K; Miura N; Ohba T; Toyokawa G; Taguchi K; Yamaguchi M; Shimokawa M; Takenoyama M
Thorac Cancer; 2019 Sep; 10(9):1779-1787. PubMed ID: 31338990
[TBL] [Abstract][Full Text] [Related]
20. Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.
Zhao Y; Zhang B; Wang S; Qiao R; Xu J; Zhang L; Zhang Y; Han B
Clin Lung Cancer; 2019 Nov; 20(6):e631-e637. PubMed ID: 31362880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
